Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …

Localized prostate cancer shows great clinical, genetic and environmental heterogeneity;
however, prostate cancer treatment is currently guided solely by clinical staging, serum PSA …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

The use of artificial intelligence (AI) to assist biomedical imaging have demonstrated its high
accuracy and high efficiency in medical decision-making for individualized cancer medicine …

In the 2022 fifth edition of the WHO Classification of Endocrine Tumours and of Central
Nervous System Tumours, pituitary adenomas are reclassified as neuroendocrine tumours …

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk
assessment after a prostate cancer diagnosis and for the care of patients with localized …

Intraductal carcinoma of the prostate (IDC-P) is a lethal prostate cancer subtype that
generally coexists with invasive high-grade prostate acinar adenocarcinoma (PAC) but …

The Gleason system forms the basis for prostate cancer grading worldwide. It has been
modified on several occasions, most recently after the International Society of Urological …

Objective The objective of the French Urology Association Cancer Committee is to propose
an update of the recommendations for the diagnosis and management of prostate cancer …

Aims A cribriform pattern, reactive stroma (RS), PTEN, Ki67 and ERG are promising
prognostic biomarkers in primary prostate cancer (PCa). We aim to determine the relative …